证券代码：688298 证券简称：东方生物 公告编号：2026-002 | 产品名称（中文） | 证书编号 | 适用国 | 预期用途（中文） | 有效期 | 持证公司/ | | --- | --- | --- | --- | --- | --- | | | | 家/地区 | | | 或生产企业 | | 肌酸激酶同工酶 检测试剂盒(时 超敏-肌钙蛋白 I 间分辨荧光免疫 | 82444370309 | | 适用于体外定量检测人血清、血浆和全 血中肌酸激酶同工酶浓度，用于辅助诊 该产品适用于体外定量检测人血清、血 浆和全血中超敏-肌钙蛋白 I 的浓度。主 | 2025/9/19 - 2030/9/18 2025/9/19 - 2030/9/18 | 东方生物 | | 间分辨荧光免疫 | | | 断心肌梗塞。本产品仅限专业人员使用， | | | | | | | 仅用于体外诊断。 | | | | 层析法) | | | | | | | 测定试剂盒(时 | | | | | | | | 82444370308 | | 要用于辅助诊断由急性心肌梗死及其他 | | | | | | | 疾病引起的心肌损伤。仅用于体外诊断， | ...

Core Viewpoint - The company and its subsidiary Hangzhou Danwei have recently obtained multiple medical device product registration certificates, enhancing their product offerings and market reach [1] Domestic Developments - Hangzhou Danwei's Mycoplasma pneumoniae nucleic acid detection kit (fluorescent PCR method) has been registered, with a validity period until January 18, 2031 [1] International Developments - The company has received registration certificates for several products, including the creatine kinase isoenzyme detection kit, in Brazil and the European Union, with varying validity periods [1] Product Portfolio Enhancement - The recent certifications supplement the company's pneumonia detection product series and improve the layout of time-resolved fluorescence immunochromatography products, expanding the sales regions [1] Sales Performance Outlook - Actual sales performance from these newly registered products cannot be predicted at this time [1]

Group 1 - The company announced the approval of a proposal to terminate certain fundraising investment projects and permanently supplement remaining raised funds for working capital during the first extraordinary general meeting of shareholders in 2026 [2]

国浩律师（杭州）事务所 关 于 浙江东方基因生物制品股份有限公司 2026 年第一次临时股东会 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二六年一月 国浩律师（杭州）事务所 法律意见书 国浩律师（杭州）事务所 关 于 浙江东方基因生物制品股份有限公司 2026 年第一次临时股东会 法律意见书 致：浙江东方基因生物制品股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）接受浙江东方基因生物制品 股份有限公司（以下简称"公司"）委托，指派律师出席公司 2026 年第一次临 时股东会（ ...

（一） 股东会召开的时间：2026 年 1 月 13 日 证券代码：688298 证券简称：东方生物 公告编号：2026-001 浙江东方基因生物制品股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （二） 股东会召开的地点：浙江省湖州市安吉县递铺街道阳光大道东段东方基 因会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 128 | | --- | --- | | 普通股股东人数 | 128 | | 2、出席会议的股东所持有的表决权数量 | 100,611,304 | | 普通股股东所持有表决权数量 | 100,611,304 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 52.5673 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 52.5673 ...

Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]

浙江东方基因生物制品股份有限公司 2026 年第一次临时股东会 证券简称：东方生物 证券代码：688298 浙江东方基因生物制品股份有限公司 2026 年第一次临时股东会会议资料 2026 年 1 月 1 浙江东方基因生物制品股份有限公司 2026 年第一次临时股东会 浙江东方基因生物制品股份有限公司 2026 年第一次临时股东会会议须知 为维护浙江东方基因生物制品股份有限公司（以下简称"公司"）全体股东 的合法权益，确保股东会的正常秩序和议事效率，保证股东会如期、顺利召开， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规 则》《浙江东方基因生物制品股份有限公司章程》《浙江东方基因生物制品股份 有限公司股东会议事规则》等相关规定，特制定本股东会会议须知。 一、为保证本次股东会的严肃性和正常秩序，切实维护与会股东（或股东代 表）的合法权益，除出席会议的股东（或股东代表），列席会议的公司董事、高 级管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他人员进入 会场。 二、出席会议的股东（或股东代表）须在会议召开前 30 分钟到会议现场办 理签到手续，并按股东会通知的相关要求，出示自 ...

Group 1 - The fentanyl concept index rose by 4.74%, ranking 6th among concept sectors, with 8 stocks increasing in value, including Botao Bio which hit a 20% limit up [1] - The leading stocks in the fentanyl sector included Dongfang Bio, Lingrui Pharmaceutical, and ST Renfu, which rose by 5.12%, 4.88%, and 2.26% respectively [1] Group 2 - The fentanyl concept sector saw a net inflow of 55 million yuan, with ST Renfu leading the inflow at 69.89 million yuan, followed by Guoyao Shares, Guoyao Modern, and Lingrui Pharmaceutical [2] - The net inflow ratios for ST Renfu, Guoyao Modern, and Guoyao Shares were 14.70%, 7.69%, and 5.96% respectively, indicating strong interest from major funds [3]

Core Viewpoint - The in vitro diagnostic (IVD) sector is experiencing significant growth, with a notable increase in stock performance among key companies in the industry, driven by strong downstream demand and market expansion [1] Group 1: Market Performance - As of September 22, the IVD sector saw an overall increase of 3.13%, ranking high on the stock performance list [1] - Notable stock performances include: - Bohui Innovation reached a limit-up - Lide Man surged by 11.76% - Shuoshi Biology and Daan Gene increased by 9.17% and 9.01% respectively - Other companies like Dongfang Biology, Shengxiang Biology, Mingde Biology, BGI, Libang Instruments, and Wantai Biology also saw gains exceeding 6% [1] Group 2: Industry Growth - The IVD industry is primarily utilized in hospital laboratories, independent clinical laboratories (ICL), health check centers, epidemic prevention stations, and blood stations [1] - The downstream demand is robust, with IVD growth nearing 20% [1] - In 2018, the revenue from public hospitals for IVD products reached 315.7 billion yuan, with a year-on-year growth rate of 12.48% [1] - Key clients such as ICL and health check centers are also experiencing growth rates around 20% or higher [1] Group 3: Market Size and Comparison - The Chinese IVD industry size reached 71.3 billion yuan in 2018, reflecting a year-on-year growth of 25.6%, significantly outpacing the global IVD market growth of 6.0% [1] - The strong downstream demand is driving rapid growth in the upstream market size [1] - The IVD sector is nurturing large enterprises, and the favorable conditions in specific segments make leading stocks with performance support worth monitoring [1]

Core Viewpoint - The company has decided to terminate certain fundraising investment projects and permanently supplement the remaining funds into working capital for daily operations, which requires shareholder approval [30][31][36]. Group 1: Board Meeting Resolutions - The board meeting held on December 25, 2025, approved the proposal to terminate the "Technology Research and Development Center Construction Project" and to permanently supplement the remaining funds into working capital [2][30]. - The board also approved the establishment of a "Securities Investment Management System" [3]. - A notice for the 2026 first extraordinary shareholders' meeting was also approved [4]. Group 2: Fundraising Project Details - The company raised a total of RMB 637.5 million through its initial public offering, with a net amount of RMB 550.8 million after expenses [7][31]. - The "Marketing Network and Information Management Platform Construction Project" has reached its intended usable state, and the remaining funds will be used for daily operations [10][12]. - As of December 23, 2025, the project had a total investment of RMB 86.1655 million, with a surplus of RMB 9.5162 million [10][12]. Group 3: Reasons for Termination of Projects - The termination of the "Technology Research and Development Center Construction Project" is due to the inability to proceed with construction during the global public health crisis from 2020 to 2022, leading to a reassessment of funding needs [33][34]. - The company has utilized its own funds for the construction of the research center, which has already been completed, making further investment in the original project unnecessary [34][35]. Group 4: Shareholder Meeting Information - The 2026 first extraordinary shareholders' meeting is scheduled for January 13, 2026, and will utilize both on-site and online voting methods [14][15]. - Shareholders must register for the meeting by providing necessary documentation, and the meeting will be held at the company's headquarters [21][25].